GlassScriptPhysician profile
Alison Peden
NPI 1760771588
$2,891.03
in general payments reported to CMS, 2019-2025
25 companies · $751 in 2025
The $751 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $675 · 2023: $753 · 2024: $463 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $641.95 | 2021-2025 | |
| Novo Nordisk INC | $439.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $285.42 | 2021-2025 | |
| Glaxosmithkline, LLC. | $229.11 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $163.90 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $125.89 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $119.04 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.72 | 2021-2023 | Trulance, Xifaxan |
| Sumitomo Pharma America, INC. | $91.32 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $82.14 | 2022 | |
| Astellas Pharma US INC | $78.71 | 2022-2025 | Veozah |
| Merck Sharp & Dohme LLC | $77.11 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $65.14 | 2023-2025 | Gvoke Hypopen |
| Amgen INC. | $59.94 | 2024 | Repatha, Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $57.24 | 2021-2025 | Airsupra, Breztri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.57 | 2021-2022 | |
| Mylan Specialty L.P. | $49.88 | 2023-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $34.08 | 2022 | |
| Genentech USA, INC. | $31.42 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $30.47 | 2022-2023 | Linzess |
| Edwards Lifesciences Corporation | $19.18 | 2023 | Sapien 3 Ultra Resilia |
| Inspire Medical Systems, INC. | $17.54 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $16.42 | 2024 | Voquezna |
| Ethicon US, LLC | $13.36 | 2021 | |
| Almatica Pharma LLC | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Peden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.